# Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma

> **NCT02094391** · PHASE2 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 4 (actual)

## Conditions studied

- In-transit Metastases Melanoma Stage IIIB and IIIC

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02094391
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2016-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02094391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02094391, "Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02094391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*